People · Operator
Named in public records as an officer, director or promoter · active 2012–2012 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Infinity Pharmaceuticals, Inc. | — | Biotechnology | Series C | $78.5M | $3.2B | 2012 |
Steve H Holtzman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steve H Holtzman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Norman C. Selby | 1 | 4 |
| Anthony B. Evnin | 1 | 4 |
| Thomas J. Lynch | 1 | 3 |
| Ian F. Smith | 1 | 2 |
| Gwen A. Fyfe | 1 | 2 |
| Julian Q. Adams | 1 | 1 |
| Michael C. Venuti | 1 | 1 |
| Vito J. Palombella | 1 | 1 |
| Pedro J. Santabarbara | 1 | 1 |
| Eric S. Lander | 1 | 1 |
| Patrick P Lee | 1 | 1 |
| Adelene Q. Perkins | 1 | 1 |
| Martin H Babler | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.